Texas Diabetes & Endocrinology, P.A.
Welcome,         Profile    Billing    Logout  
 19 Trials 
61 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Palal, Betsy
TRANSCEND-T2D-2, NCT06260722: Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor

Recruiting
3
1250
Canada, US, RoW
Retatrutide, LY3437943, Semaglutide
Eli Lilly and Company
Diabetes Mellitus, Type 2
12/26
03/27
QWINT-4, NCT05462756 / 2021-005878-25: A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

Completed
3
730
Europe, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Lispro (U100), Humalog, Insulin Glargine (U100), Basaglar
Eli Lilly and Company, Eli Lilly and Company
Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
02/24
02/24
QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

Completed
3
692
Europe, Japan, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec
Eli Lilly and Company
Type 1 Diabetes, Diabetes
05/24
05/24
SURMOUNT-5, NCT05822830: A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

Completed
3
751
US
Tirzepatide, LY3298176, Semaglutide
Eli Lilly and Company
Obesity, Overweight
11/24
11/24
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
Blevins, Thomas C
NCT05706506: A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

Completed
4
152
US
Tirzepatide, LY3298176
Eli Lilly and Company
Type 2 Diabetes, Diabetes Mellitus, Type 2
10/23
10/23
MKC-TI-193, NCT05904743: INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes

Completed
4
141
US
Afrezza, Technosphere Insulin, insulin degludec, Rapid-acting Insulin Analog, any FDA approved Rapid-acting Insulin Analog, Basal Insulin, any FDA approved Basal Insulin
Mannkind Corporation, Jaeb Center for Health Research
Diabetes Mellitus, Type 1
03/24
06/24
QWINT-4, NCT05462756 / 2021-005878-25: A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

Completed
3
730
Europe, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Lispro (U100), Humalog, Insulin Glargine (U100), Basaglar
Eli Lilly and Company, Eli Lilly and Company
Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
02/24
02/24
PALISADE, NCT05089084 / 2021-003680-10: Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

Active, not recruiting
3
75
Europe, Canada, Japan, US, RoW
Plozasiran, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Familial Chylomicronemia
04/24
04/26
QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

Completed
3
692
Europe, Japan, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec
Eli Lilly and Company
Type 1 Diabetes, Diabetes
05/24
05/24
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting
3
3000
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Overweight or Obesity
07/25
07/27
TRIUMPH-3, NCT05882045: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Active, not recruiting
3
1800
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Cardiovascular Diseases
01/26
02/26
SECURE-T2D, NCT05815342: OP5-005 Using Omnipod 5 in Adults With Type 2

Completed
N/A
343
US
Omnipod 5 Automated Glucose Control System
Insulet Corporation, Jaeb Center for Health Research
Type2 Diabetes
03/24
03/24
2IQP, NCT05785832: A Randomized Trial Evaluating Control-IQ Technology in Adults With Type 2 Diabetes

Completed
N/A
319
Canada, US
t:slim X2 insulin pump with Control-IQ technology 1.5 and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM)
Tandem Diabetes Care, Inc., Jaeb Center for Health Research
Type 2 Diabetes Treated With Insulin
09/24
09/24
Smith, Timothy W
SURPASS-EARLY, NCT05433584: A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

Active, not recruiting
4
780
Europe, Canada, US, RoW
Tirzepatide, LY3298176, Antihyperglycemic medication
Eli Lilly and Company
Type 2 Diabetes
10/25
11/27
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
TRIUMPH-5, NCT06662383: A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

Recruiting
3
800
Europe, US, RoW
Retatrutide, LY3437943, Tirzepatide, LY3298176
Eli Lilly and Company
Obesity
04/27
04/27
SURMOUNT-5, NCT05822830: A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

Completed
3
751
US
Tirzepatide, LY3298176, Semaglutide
Eli Lilly and Company
Obesity, Overweight
11/24
11/24
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

Active, not recruiting
3
1500
Europe, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Type 2 Diabetes
08/25
08/25
TRIUMPH-3, NCT05882045: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Active, not recruiting
3
1800
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Cardiovascular Diseases
01/26
02/26
TRIUMPH-1, NCT05929066: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

Active, not recruiting
3
2300
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea
04/26
05/26
TRIUMPH-2, NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Active, not recruiting
3
1000
Europe, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
05/26
05/26
NCT05976243: A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

Recruiting
3
348
Europe, Canada, Japan, US, RoW
Remibrutinib, Placebo
Novartis Pharmaceuticals
Chronic Inducible Urticaria
07/26
12/28
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
NCT04804033: A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

Terminated
2/3
538
US
BHV-3500 (zavegepant), Placebo
Pfizer
Migraine
03/24
03/24
OA05, NCT05620563: A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 In Participants With Osteoarthritis Pain

Completed
2
147
US
LY3857210, Placebo
Eli Lilly and Company
Osteoarthritis
06/23
06/23
NCT05630196: A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Chronic Low Back Pain

Completed
2
138
US
LY3857210, Placebo
Eli Lilly and Company
Chronic Low-back Pain
06/23
06/23
NCT05620576: A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).

Completed
2
131
US
LY3857210, Placebo
Eli Lilly and Company
Diabetic Peripheral Neuropathic Pain
07/23
08/23
NCT06143956: A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Recruiting
2
1040
US, RoW
LY3305677, LY3841136, Tirzepatide, Placebo, LY3549492
Eli Lilly and Company
Obesity, Overweight
06/26
09/26
NCT06230523: A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

Recruiting
2
250
US, RoW
LY3841136, Placebo
Eli Lilly and Company
Obesity, Overweight and Obesity
06/25
09/25
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

Completed
2
797
NA
ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline
AEON Biopharma, Inc., PPD
Migraine
06/24
08/24
NCT06568042: Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy

Recruiting
2
450
Europe, Canada, Japan, US, RoW
LY3848575, Placebo
Eli Lilly and Company
Neuropathic Pain, Distal Sensory Polyneuropathy
06/26
09/26
NCT06603571: A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Recruiting
2
350
US, RoW
LY3841136, Tirzepatide, Placebo
Eli Lilly and Company
Obesity, Overweight
06/26
08/26
NCT06683508: A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

Recruiting
2
275
US, RoW
LY3549492, Placebo
Eli Lilly and Company
Obesity, Overweight
04/26
09/26
NCT06124807: A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

Active, not recruiting
2
179
US, RoW
LY3305677, Placebo
Eli Lilly and Company
Obesity, Overweight and Obesity
01/25
05/25
NCT06074562: A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain

Recruiting
2
410
Europe, Japan, US, RoW
LY3556050, Placebo
Eli Lilly and Company
Diabetic Peripheral Neuropathy
07/25
07/25
CYPRESS, NCT05895552: A Phase 2 Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain

Recruiting
2
384
US
RTA 901, BIIB143, Cemdomespib, RTA 901-Matching Placebo
Reata, a wholly owned subsidiary of Biogen
Diabetic Peripheral Neuropathic Pain
08/26
08/26
CPMP, NCT05986292: A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain

Recruiting
2
10000
US
LY3016859 ISA, LY3556050 ISA, LY3526318 ISA, LY3857210 ISA, Placebo Oral, Placebo
Eli Lilly and Company
Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain
04/27
04/27
MoVeUP, NCT05386355: Improving Pediatric COVID-19 Vaccine Uptake Using an mHealth Tool

Completed
N/A
727
US
COVID-19 Vaccine Uptake App, General Health App
IDeA States Pediatric Clinical Trials Network, National Institutes of Health (NIH), University of Nebraska, University of Montana
COVID-19 Vaccines, Telemedicine, Vaccine Hesitancy, Pediatric ALL
09/23
09/23
NCT06095531: A Pilot Study to Evidence Improved Cranial Flap Fixation With a Bioresorbable Bone Adhesive

Recruiting
N/A
20
US
Tetranite for Cranial Flap Fixation (TN-CFF)
RevBio
Craniotomy
09/24
03/25
NCT05537818: AVPI Migraine Study

Recruiting
N/A
80
US
AVPI Device
Nocira, LLC
Migraine
12/23
01/24
SyncAV, NCT04100148: Post-Market Trial

Active, not recruiting
N/A
1686
Europe, Canada, Japan, US, RoW
SyncAV programmed ON, Fixed AV delay
Abbott Medical Devices
Congestive Heart Failure
06/25
12/25
PROTECT IV, NCT04763200: Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

Recruiting
N/A
1252
Europe, Canada, US
Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump
Abiomed Inc.
Left Ventricular Dysfunction, Coronary Artery Disease
03/26
10/27
Tran, Hien T
QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

Completed
3
692
Europe, Japan, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec
Eli Lilly and Company
Type 1 Diabetes, Diabetes
05/24
05/24
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
TRIUMPH-3, NCT05882045: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Active, not recruiting
3
1800
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Cardiovascular Diseases
01/26
02/26
OPTI-2, NCT06238778: Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec

Recruiting
2
230
US
HDV-Lispro, HDV-L, Lispro, LIS
Diasome Pharmaceuticlas, Inc.
Diabetes Mellitus, Type 1
06/25
12/25
NCT06719531: SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients with Type 1 and Type 2 Diabetes

Not yet recruiting
N/A
1500
US
Continuous Glucose Monitoring
Medtronic Diabetes
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
12/25
12/25
Ozer, Kerem
MATILDA, NCT05632276: A Prospective, Multi Centre, Interventional, Non-comparator, Open Label Study to Demonstrate the Efficacy, Performance and Safety of ConvaFoam™ Silicone, ConvaFoam™ Border and ConvaFoam™ Non-Adhesive Dressings in the Management of Surgical and Traumatic Wounds

Completed
N/A
54
US
ConvaFoam, ConvaFoam Silicone, ConvaFoam Border, ConvaFoam Non Adhesive
ConvaTec Inc.
Surgical Wound, Trauma-related Wound
03/24
03/24
NCT05805046: Study of Avelle™ Negative Pressure Wound Therapy (NPWT) System

Withdrawn
N/A
59
US
Negative Pressure Wound Therapy System, Avelle™ Negative Pressure Wound Therapy System
ConvaTec Inc.
Surgical Wound, Recent, Surgical Wound Leak, Dehiscence Wound, Trauma-related Wound
10/23
10/23
Robitaille, Yves
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
MUIR-3, NCT06347133: Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Recruiting
3
1328
Europe, Canada, US, RoW
Plozasiran Injection, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Hypertriglyceridemia
07/26
10/26
SHASTA-4, NCT06347016: Study of Plozasiran in Adults With Severe Hypertriglyceridemia

Recruiting
3
300
Europe, Canada, US, RoW
Plozasiran Injection, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Severe Hypertriglyceridemia
07/26
10/26
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
TRIUMPH-3, NCT05882045: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Active, not recruiting
3
1800
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Cardiovascular Diseases
01/26
02/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
STARLIGHT, NCT06613698: A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease

Not yet recruiting
2
393
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline
Liver Diseases, Alcoholic
12/26
03/27

Download Options